Wockhardt has surged 9% to Rs 512 in early morning deals on BSE after the pharmaceutical firm said the UK health regulator has allowed its Kadaiya, Nani Daman facility to manufacture and supply most of the products approved to be produced at the unit.
The company has received communication from the United Kingdom Medicines and Healthcare Products Regulatory Agency whereby they have allowed the company to manufacture and supply most of the products manufactured at the said facility and assessed to be critical to public health, Wockhardt said in a statement.
As a result the net impact on the annualised consolidated revenue is expected to be less than £1 million, out of the total annual consolidated revenue of approximately £18 million, from the said facility, it added.
The stock opened at Rs 482 and touched high of Rs 513 on BSE. A combined around one million shares have changed hands on the counter in early morning deals on BSE and NSE.
The company has received communication from the United Kingdom Medicines and Healthcare Products Regulatory Agency whereby they have allowed the company to manufacture and supply most of the products manufactured at the said facility and assessed to be critical to public health, Wockhardt said in a statement.
As a result the net impact on the annualised consolidated revenue is expected to be less than £1 million, out of the total annual consolidated revenue of approximately £18 million, from the said facility, it added.
The stock opened at Rs 482 and touched high of Rs 513 on BSE. A combined around one million shares have changed hands on the counter in early morning deals on BSE and NSE.
